Patient Compliance: Sweetening the Pill
Publisher: Gower Publishing Company | ISBN: 0566086581 | edition 2006 | PDF | 220 pages | 11 mb

Vast global resources are ploughed into the delivery of treatment interventions ranging from diet and lifestyle advice through to complex surgery. In all cases, whatever the intervention, unless the recipient is engaged with the process and understands why the intervention has been offered and the part they play in its success, compliance will be an issue. Even where the individual does engage and understand, he or she may choose, in the light of that knowledge, not to comply. This book aims to explore the key factors which drive compliance and the part that healthcare professionals can play in improving this, with the key underlying goal of improving public health in its broadest sense.




John P. Griffin, "The Textbook of Pharmaceutical Medicine"
BMJ Books / Wiley-Blackwell | 2009 | ISBN: 1405180358 | 776 pages | PDF | 3,8 MB

The Textbook of Pharmaceutical Medicine is a standard reference for all those working in pharmaceutical medicine and the recognised text for the UK Faculty of Pharmaceutical Medicine Diploma. This is a comprehensive volume covering the processes by which medicines are developed, tested and approved. Regulations for drug development in the UK, EU, USA, Australia and Japan are discussed, providing relevant information for drug approval in the main continents where new drugs are developed.

The chapters are written by leading academics, medical directors and lawyers, providing authoritative and in-depth information for trainees on the Faculty course, and for physicians working in the pharmaceutical industry. As well as thorough updating of the regulatory chapters, the 6th edition includes chapters on these vital new areas:
Paediatric regulation
Ethics
Due diligence and the pharmaceutical physician











John Block, John M Beale, "Wilson & Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry"
Lippincott Williams & Wilkins | 2003 | ISBN: 0781734819 | 1000 pages | PDF (scan) | 213 MB

Oregon State Univ., Corvallis. Blends the chemical and pharmaceutical principles necessary for understanding structure-activity relationships and molecular mechanisms of drug action. Offers new information on emerging trends and advances and the challenges posed by new diseases. Features a new chapter on combinatorial chemistry.


Part 1







Part 2







Part 3











Sarfaraz K. Niazi, "Handbook of Pharmaceutical Manufacturing Formulations, Second Edition: (Six-Volume Set)"
Informa Healthcare | 2009 | ISBN: 1420081063, 1420081306, 1420081284, 1420081268, 1420081233, 1420081187, 1420081160 | 2094 pages | PDF | 16,2 MB


Includes:
Volume 1: Compressed Solid Products
Volume 2: Uncompressed Solid Products
Volume 3: Liquid Products
Volume 4: Semisolid Products
Volume 5: Over-the-Counter Products
Volume 6: Sterile Products

An authoritative and practical guide to the art and science of formulating drugs.

With thoroughly revised and expanded content, this Second Edition six-volume set compiles volumes from FDA New Drug Applications, patent applications, and other sources of generic and proprietary formulations to cover the broad spectrum of issues concerning drug manufacturing.

A must-have collection for pharmaceutical manufacturers, educational institutions, and regulatory authorities, this set is an excellent platform for drug companies to benchmark their products and for generic companies to formulate drugs coming off patent.

As the largest reference on pharmaceutical formulations, this handbook also provides guidelines on how to file aNDAs in the shortest possible time, helping pharmaceutical companies to cut costs in the areas of pharmaceutical research and development.

Divided conveniently into two parts—regulatory and manufacturing guidelines, and formulations—each volume in the set covers:

* cGMP compliance
* pre-approval inspections
* stability and bioequivalence testing
* packaging commodity development
* common difficulties in formulating drugs
* changes to aNDAs














Giles D. Moss, "Pharmaceuticals-where's the Brand Logic?: Branding Lessons and Strategy"
Informa Healthcare | 2007 | ISBN: 0789032589, 0789032597 | 248 pages | PDF | 10,8 MB

Insights and analysis that challenge current thought on consumer branding theory and strategy

Pharmaceutical companies need to go beyond simply relying on strong sales forces and innovative research and development to succeed. Effective branding strategy is essential. Pharmaceuticals--Where's the Brand Logic?: Branding Lessons and Strategy discusses in detail the application of current consumer branding theory to pharmaceutical marketing. This comprehensive book pulls information from fast moving consumer goods (FMCG) research and brand theory and applies it to the pharmaceutical world. It looks at branding on multiple levels within the pharmaceutical industry, including the industry brand, the corporate brand, the franchise brand, and the global and local product brand. Practical strategies are extensively explained and future challenges facing the pharmaceutical industry are explored, all geared to help any pharmaceutical professional to successfully market their brand.

Pharmaceuticals--Where's the Brand Logic?: Branding Lessons and Strategy may well become a daily reference for anyone in the industry, providing in a single volume a framework for the organization of a brand portfolio for any pharmaceutical company. This unique resource challenges traditional thought about the concept of branding in the pharmaceutical industry, examining several of the most difficult branding theory issues. This helpful guide provides several figures to fully explain data.

Topics in Pharmaceuticals--Where's the Brand Logic?: Branding Lessons and Strategy include:

What is branding
How is branding applied to the FMCG and pharmaceutical industries
Corporate brands--and how they can be leveraged
Franchise branding as a business strategy
Developing and sustaining pharmaceutical brands over time
Saving the credibility of the pharmaceutical industry
Changing the pharmaceutical business model to use branding as a strategic tool
And much, more


Pharmaceuticals--Where's the Brand Logic?: Branding Lessons and Strategy provides the information and tools to help gain the competitive edge in a tough marketplace. This is an invaluable resource for anyone in the global pharmaceutical industry, including marketing personnel, senior management, general managers, strategy groups, and training departments.











Sean C. Sweetman, Paul S Blake, Julie M. McGlashan, Gail C. Neatherco, «Martindale: The Complete Drug Reference - 35th Edition»
Pharmaceutical Press ISBN 085369687X 35th Edition - 2007 Format ISO 3322 Pages 470,0 Mb

Martindale: The complete drug reference has been continuously expanded since it was first published in 1883. In this 35th edition, every entry hasbeen checked and updated where necessary. The extra information, and largertext size chosen to make the books easier to read, is contained in a new cased two-volume format. The first volume contains the preface and the drugmonographs, while the second volume holds all proprietary preparations and the index, as well as manufacturers' contact information


British National Formulary for Children 2009
By Paediatric Formulary Committee

Publisher: Pharmaceutical Press 2009 974 Pages ISBN: 0853698473 PDF 6.11 MB

BNF for Children (BNFC) provides essential practical information to all healthcare professionals involved in the prescribing, dispensing, monitoring and administration of medicines to children. The resource addresses a significant knowledge gap in many areas of paediatric practice by providing practical information on the use of medicines in children of all ages from birth to adolescence.



Melvyn Little PhD, "Recombinant Antibodies for Immunotherapy"
Cambridge University Press 2009 ISBN: 0521887321 440 pages PDF 3,8 MB

Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, "arming" mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.